ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
Dow Jones
42.840,26
1,18%
Euro vs US Dollar
1,043
0,00%
Bitcoin
96.922,04
-0,29%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Enlivex Therapeutics Ltd (ENLV) Börsenkurse

Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd (ENLV)

NASDAQ
1,24
0,06
(5,08%)
Geschlossen 22 Dezember 10:00PM
Verzögert um 15 Minuten
1,27
0,03
(2,42%)
Nach Börsenschluss: 1:49AM
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
1,27
Gebot
1,12
Fragen
1,34
Volumen
141.570
1,16 Tagesbereich 1,25
0,8101 52-Wochen-Bereich 4,59
Marktkapitalisierung
26,518M
Handelsende
1,18
Handelsbeginn
1,19
Letzte Trade
21
@
1.26
Letzter Handelszeitpunkt
Finanzvolumen
US$ 172.248
VWAP
1,2167
Durchschnittliches Volumen (3 Mio.)
238.495
Ausgegebene Aktien
20.880.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,89
Gewinn pro Aktie (EPS)
-1,39
Erlöse
-
Nettogewinn
-29,07M

Über Enlivex Therapeutics Ltd

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threate... Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms. Mehr anzeigen

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Website
www.enlivex.com
Hauptsitz
Ness Ziona, Center, Isr
Gegründet
-
Enlivex Therapeutics Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ENLV. The last closing price for Enlivex Therapeutics was US$1,18. Over the last year, Enlivex Therapeutics shares have traded in a share price range of US$ 0,8101 to US$ 4,59.

Enlivex Therapeutics currently has 20.880.000 shares in issue. The market capitalisation of Enlivex Therapeutics is US$24,64 million. Enlivex Therapeutics has a price to earnings ratio (PE ratio) of -0.89.

ENLV Neueste Nachrichten

Weitere Nachrichten

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

11 Dezember 2024
Edgar (US Regulatory)

Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis

Ness-Ziona, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

11 Dezember 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

03 Dezember 2024
Edgar (US Regulatory)

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

03 Dezember 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

29 November 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

20 November 2024
Edgar (US Regulatory)

Enlivex Adopts Bitcoin Treasury Reserve Strategy

Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

20 November 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

14 November 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

14 November 2024
Edgar (US Regulatory)

Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis

Nes-Ziona, Israel, Nov. 14, 2024 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced...

14 November 2024
GlobeNewswire Inc.
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.03983.235246301411.23021.271.131310021.18484509CS
40.40050146.06112255450.8694991.34650.834347261.25134446CS
12-0.32-20.12578616351.591.750.81012384951.28799999CS
26-0.06-4.511278195491.331.750.81011483741.32753822CS
52-0.36-22.08588957061.634.590.81011460601.86078717CS
156-4.97-79.64743589746.248.640.8101762812.78451819CS
260-7.8838-86.12598046719.153829.40.81011753178.94689167CS

ENLV - Frequently Asked Questions (FAQ)

What is the current Enlivex Therapeutics share price?
The current share price of Enlivex Therapeutics is US$ 1,27
How many Enlivex Therapeutics shares are in issue?
Enlivex Therapeutics has 20.880.000 shares in issue
What is the market cap of Enlivex Therapeutics?
The market capitalisation of Enlivex Therapeutics is USD 24,64M
What is the 1 year trading range for Enlivex Therapeutics share price?
Enlivex Therapeutics has traded in the range of US$ 0,8101 to US$ 4,59 during the past year
What is the PE ratio of Enlivex Therapeutics?
The price to earnings ratio of Enlivex Therapeutics is -0,89
What is the reporting currency for Enlivex Therapeutics?
Enlivex Therapeutics reports financial results in USD
What is the latest annual profit for Enlivex Therapeutics?
The latest annual profit of Enlivex Therapeutics is USD -29,07M
What is the registered address of Enlivex Therapeutics?
The registered address for Enlivex Therapeutics is 14 EINSTEIN STREET, NESS ZIONA, CENTER, 7403618
What is the Enlivex Therapeutics website address?
The website address for Enlivex Therapeutics is www.enlivex.com
Which industry sector does Enlivex Therapeutics operate in?
Enlivex Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
120,01M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
76,64M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
33,95M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,61k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
120,4M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,5M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,63M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,84M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
8,58M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
5,96M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,32M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
305,1M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
292,16M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
287,21M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
277,63M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
ENLV
Enlivex Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten